Cardiomyopathy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have signed a consent form approved by an ethics committee before any trial procedures begin (or whose legal representative has signed on their behalf)
- People who have been diagnosed with obstructive hypertrophic cardiomyopathy (a condition where the heart muscle is abnormally thick and blocks blood flow), meeting all of the following: thickened heart muscle of 15mm or more (or 13mm or more if a family member has the same condition), no other explanation for the thickening such as high blood pressure or valve disease, and a significant blockage to blood flow out of the heart measured at rest, during a breathing manoeuvre, or after exercise
- People whose heart pumping strength (ejection fraction) is 55% or higher at the start of the trial
- People who have previously taken the drug mavacamten continuously for 16 weeks or more, are currently taking it, or are scheduled to start taking it
- People who have been taking a stable dose of the drug cibenzoline for at least 3 months before starting mavacamten (people who gradually reduced their cibenzoline dose within the 3 months before starting mavacamten may also be eligible, provided they had been on a stable dose for at least 3 months before that reduction began)
- People who are at least 18 years old at the time of signing the consent form
Who may not be able to join:
- People who have had an allergic reaction to mavacamten or any of its ingredients
- People who are pregnant, or women who could become pregnant
- People currently taking certain strong medications that affect how the body processes drugs (including itraconazole, clarithromycin, voriconazole, posaconazole, ritonavir, cobicistat, ceritinib, ensitrelvir fumaric acid, lonafarnib, josamycin, or mifepristone/misoprostol)
- People with severe liver disease (classified as Child-Pugh C) (confirm with trial site)
- People with severe heart rhythm or electrical conduction problems affecting how signals travel through the heart
- People with congestive heart failure (where the heart cannot pump blood effectively enough to meet the body's needs)
- People who require dialysis (kidney filtering treatment)
- People with a type of eye condition called angle-closure glaucoma
- People who have difficulty emptying their bladder
- People currently taking any of the following medications: vardenafil hydrochloride hydrate, moxifloxacin hydrochloride, lascufloxacin hydrochloride (injection), toremifene citrate, fingolimod hydrochloride, siponimod fumarate, or eliglustat tartrate
- People who have taken mavacamten within 8 weeks before the start of the trial (confirm with trial site how this is assessed)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Bristo Myers Squibb, Bristo Myers Squibb
Phone: 855-907-3286
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in either resting or Valsalva Left Ventricular Outflow Tract (LVOT) peak gradient whichever used to judge the initiation of mavacamten treatment
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.